TERNS PHARMACEUTICALS INC (TERN:NASDAQ)
$52.71 0.03 (0.0569%)
Analysed TERNS PHARMACEUTICALS INC (TERN:NASDAQ) News Sources
AZN vs. MRK: Which Oncology Stock Offers Better Investment Potential?
09-04-2026
yahoo.com
Why Terns Pharmaceuticals Stock Rocked the Market in March
08-04-2026
fool.com
Merck’s Terns Deal Targets Cancer Pipeline And Keytruda Patent Risks
07-04-2026
yahoo.com
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
07-04-2026
yahoo.com
Terns rebuffed a higher bid before selling to Merck
07-04-2026
biopharmadive.com
Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho
06-04-2026
yahoo.com
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
02-04-2026
yahoo.com
Assessing Terns Pharmaceuticals (TERN) Valuation After Strong Recent Share Price Momentum
02-04-2026
yahoo.com
Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
02-04-2026
yahoo.com
Biotechs Are a Healthy Growth Bet. Thank M&A and New Drugs.
31-03-2026
yahoo.com
What is the current price of TERNS PHARMACEUTICALS INC (TERN:NASDAQ)?
The current price of TERNS PHARMACEUTICALS INC (TERN:NASDAQ) is $52.71.
TERNS PHARMACEUTICALS INC (TERN:NASDAQ) absolute price change since previous trading day?
The absolute price change of TERNS PHARMACEUTICALS INC (TERN:NASDAQ) since the previous trading day is $0.03.
TERNS PHARMACEUTICALS INC (TERN:NASDAQ) percentage price change since previous trading day?
The percentage price change of TERNS PHARMACEUTICALS INC (TERN:NASDAQ) since the previous trading day is 0.0569%.
What is the most recent average sentiment score for TERNS PHARMACEUTICALS INC (TERN:NASDAQ)?
The most recent average sentiment score for TERNS PHARMACEUTICALS INC (TERN:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for TERNS PHARMACEUTICALS INC (TERN:NASDAQ)?
The most recent sentiment for TERNS PHARMACEUTICALS INC (TERN:NASDAQ) is .
SEC-8K** Filing Available For TERNS PHARMACEUTICALS INC (TERN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.